ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1777

Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential

Isabell Haase1, Matthias Schneider1, Ralph Brinks1 and Rebecca Fischer-Betz1, 1Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany

Meeting: ACR Convergence 2020

Keywords: pregnancy, prevention, quality of care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) face a higher risk of pre-eclampsia, especially those with additional risk factors. Low dose aspirin (LDA) is known to protect against pre-eclampsia in non-autoimmune patients. Consequently, the EULAR recommends starting LDA in those women at risk preconceptionally or latest until gestational week 16. We sought to examine the use of LDA in a real-world cohort in relation to different risk factors and the provision of preconception counselling.

Methods: Pregnancies of women with SLE from an outpatient pregnancy clinic were evaluated before and throughout pregnancy. Clinical characteristics including pre-eclampsia risk factors, disease activity (SLEDAI) and medication use were analysed. Association of Aspirin use (latest from week 16 on) with different risk factors or preconception counselling was analysed using χ² tests.

Results: We enrolled 201 pregnancies in 136 women. 57.8% of pregnancies showed a high-risk profile for pre-eclampsia (history of pre-eclampsia, multifetal gestation, chronic hypertension, lupus nephritis or aPL), another 26.6% had at least one moderate risk factor (nulliparous, body mass index >30 or age >35).

LDA was administered in 43.3% of pregnancies. LDA use was significantly higher in those with a high-risk profile (63.5% vs. 16.7%) [OR 8.59 (95%-CI: 4.19-18.62), p< 0.001], but not in those with a moderate-risk profile. Still, 36.5% of those at high risk and 83% of those at moderate risk did not receive Aspirin. In a descending order, aPL, multifetal gestation, lupus nephritis and nulliparity were associated with a higher LDA use, whereas the other risk factors were not.

Preconception counselling significantly increased Aspirin administration [OR 2.36 (95%-CI: 1.23-4.63), p< 0.01], especially in those at high risk [OR 4.12 (95%-CI 1.72-10.16), p< 0.001]. Overall, LDA use increased from 1995 to 2019 (χ² test for trend in proportions, p< 0.001).

Conclusion: We found a high prevalence of pre-eclampsia risk factors in our real-world cohort of pregnant SLE patients, which was contrasted by an overall infrequent use of LDA during pregnancy. Preconception counselling prior to conception allows more women, especially those with an additional risk profile, to receive LDA at an early stage, which may contribute to a better pregnancy outcome.

Table 1: Patient characteristics and pre-conceptional risk profile


Disclosure: I. Haase, None; M. Schneider, GSK, UCB, Abbvie, 2, Abbvie, Alexion, Astra Zeneca, BMS, Boehringer Ingelheim, Gilead, Lilly, Sanofi, UCB, 5, Abbvie, Astra Zeneca, BMS, Chugai, GSK, Lilly, Pfizer, Sanofi, 8; R. Brinks, None; R. Fischer-Betz, UCB, 5, Abbvie, Amgen, Biogen, BMS, Celgene, Chugai, GSK, Janssen, Lilly, Medac, MSD, Novartis, Roche, UCB, Pfizer, 8.

To cite this abstract in AMA style:

Haase I, Schneider M, Brinks R, Fischer-Betz R. Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/low-dose-aspirin-to-prevent-pre-eclampsia-in-sle-pregnancies-counselling-helps-to-realize-our-full-potential/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-aspirin-to-prevent-pre-eclampsia-in-sle-pregnancies-counselling-helps-to-realize-our-full-potential/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology